Automated Bioanalytical Workflow for Ligand Binding-Based Pharmacokinetic Assay Development

Area of Science:

• Bioanalytical Chemistry
• Pharmacokinetics
• Monoclonal Antibody Therapeutics

Background:

• Therapeutic monoclonal antibodies (mAbs) are increasingly important, necessitating accurate pharmacokinetic (PK) measurement in serum.
• Ligand-binding assays using anti-idiotypic antibodies (anti-IDs) are common but can be affected by soluble antigens, leading to underestimation of drug levels.
• Robust PK assays require anti-IDs with high affinity, minimal interference from soluble antigens, and low matrix effects.

Purpose of the Study:

• To develop an integrated, automated screening and analysis platform for robust bioanalytical pharmacokinetic (PK) assay development.
• To efficiently screen and select optimal anti-idiotypic antibodies (anti-IDs) and assay formats for therapeutic monoclonal antibody (mAb) quantification.
• To reduce the time and resources required for developing reliable PK assays compared to traditional methods.

Main Methods:

• Developed an automated workflow and scoring platform utilizing multiple bioanalytical assay parameters for ranking anti-idiotypic antibodies (anti-IDs).
• Employed a primary indirect electrochemiluminescence (ECL) screen to shortlist anti-IDs for further testing.
• Conducted a secondary ECL sandwich assay screen with labeled anti-ID pairings to evaluate multiple PK assay formats and identified the optimal anti-ID/assay combination.

Main Results:

• Successfully developed an automated assay incorporating fixed plate maps and a human-guided graphical user interface (GUI) for scoring.
• Compared the GUI-based scoring system with a data-dependent Gaussian mixture model scoring system for automated selection.
• The automated approach significantly reduced the time and resources needed for screening anti-IDs and identifying the most robust PK assay format.

Conclusions:

• The developed automated platform enables efficient screening of anti-idiotypic antibodies (anti-IDs) and identification of optimal pharmacokinetic (PK) assay formats.
• This integrated approach enhances efficiency, quality, and robustness in bioanalytical assay development for therapeutic monoclonal antibodies (mAbs).
• Standardized, automated platforms are critical for accelerating PK assay development to support future clinical trials.